AZD5148 / AstraZeneca - LARVOL DELTA

Safety and Tolerability of AZD5148 in Japanese Participants (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults (clinicaltrials.gov) - P1 | N=84 | Active, not recruiting | Sponsor: AstraZeneca | Trial primary completion date: Feb 2025 ➔ Nov 2025

Trial primary completion date

Safety and Tolerability of AZD5148 in Japanese Participants (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults (clinicaltrials.gov) - P1 | N=84 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed

Safety and Tolerability of AZD5148 in Japanese Participants (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial • Infectious Disease

Anti-Toxin B Neutralizing Monoclonal Antibody AZD5148 Provides Protection in a Clostridioides difficile Gnotobiotic Piglet Model (IDWeek 2024) - No abstract available

Infectious Disease

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults (clinicaltrials.gov) - P1 | N=84 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial